Why Zacks? Learn to Be a Better Investor.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Impax to Sell Authorized Generic Renvela
SNY IPXL MNK
Impax Laboratories, Inc. ( IPXL - Analyst Report) announced that it has started shipping the authorized generic version of Sanofi’s ( SNY - Analyst Report) Renvela (800 mg) under its settlement agreement with the latter. The drug is approved for the control of serum phosphorus in patients suffering from chronic kidney disease (CKD) and dependent on dialysis.
We note that Impax’s settlement agreement with Sanofi allows it to sell generic versions of two other products − Renagel and Renvela (for oral suspension) starting on Sep 16, 2014, pending U.S. Food and Drug Administration (FDA) approval for its abbreviated new drug applications (ANDAs) for these products.
Meanwhile, Impax is looking to get its ANDA for generic Renvela approved by the FDA. Approval would allow the company to launch its generic version later this year. Our Take
The launch of the authorized generic version of Renvela is an important event for Impax. Renvela’s U.S. sales were about $907 million in the 12 months ended Feb 2014, as per IMS Health.
Impax expects the sale of authorized generic Renvela to generate net profits of approximately $50 million−$70 million in 2014.
Meanwhile, Impax’s Rytary is under FDA review for the symptomatic treatment of Parkinson's disease (PD). The company is looking for commercialization partners for Rytary outside the U.S.
We expect investor focus to remain on further updates from the company especially on the Hayward manufacturing facility.
Impax carries a Zacks Rank #2 (Buy). Some better-ranked stocks in the health care sector include
Mallinckrodt plc ( MNK - Analyst Report) and Actavis plc . Both stocks carry a Zacks Rank #1 (Strong Buy). Read the Full Research Report on SNY Read the Full Research Report on IPXL Read the Full Research Report on MNK Read the Full Research Report on ACT Zacks Investment Research